Keyword - Cost-Benefit Analysis

The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial.
Marson, Anthony; Burnside, Girvan; Appleton, Richard; Smith, Dave; Leach, John Paul; Sills, Graeme; Tudur-Smith, Catrin; Plumpton, Catrin; Hughes, Dyfrig A; Williamson, Paula; Baker, Gus A; Balabanova, Silviya; Taylor, Claire; Brown, Richard; Hindley, Dan; Howell, Stephen; Maguire, Melissa; Mohanraj, Rajiv; Smith, Philip E
Lancet, Volume 397, Issue 10282
PMID: 33838757 DOI: 10.1016/S0140-6736(21)00247-6 
Citations: 91 (Scopus)
Tags: PCCC 

The cost-effectiveness of seven behavioural interventions to prevent drug misuse in vulnerable populations.
Pennington, Becky; Collins, Brendan; Leigh, Simon; Martin, Antony P; Owen, Lesley; Fischer, Alastair; Sumnall, Harry; Bates, Geoff
Int J Drug Policy, Volume 57
PMID: 29679810 DOI: 10.1016/j.drugpo.2018.03.028 
Citations: 1 (Scopus)
Tags: CLAHRC 

Cost effectiveness of fall prevention programmes for older adults.
Benedetto, Valerio; Hill, James; Harrison, Joanna
Br J Community Nurs, Volume 27, Issue 11
PMID: 36327206 DOI: 10.12968/bjcn.2022.27.11.530 
Citations: 1 (Scopus)
Tags: MIDAS